Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Cash & Equivalents: 2010-2024

Historic Cash & Equivalents for Sunshine Biopharma (SBFM) over the last 12 years, with Dec 2024 value amounting to $9.7 million.

  • Sunshine Biopharma's Cash & Equivalents fell 23.76% to $9.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.3 million, marking a year-over-year decrease of 23.76%. This contributed to the annual value of $9.7 million for FY2024, which is 40.55% down from last year.
  • As of FY2024, Sunshine Biopharma's Cash & Equivalents stood at $9.7 million, which was down 40.55% from $16.3 million recorded in FY2023.
  • Sunshine Biopharma's Cash & Equivalents' 5-year high stood at $21.8 million during FY2022, with a 5-year trough of $989,888 in FY2020.
  • Its 3-year average for Cash & Equivalents is $15.9 million, with a median of $16.3 million in 2023.
  • As far as peak fluctuations go, Sunshine Biopharma's Cash & Equivalents surged by 2,344.11% in 2020, and later tumbled by 40.55% in 2024.
  • Yearly analysis of 5 years shows Sunshine Biopharma's Cash & Equivalents stood at $989,888 in 2020, then surged by 106.61% to $2.0 million in 2021, then soared by 967.22% to $21.8 million in 2022, then fell by 25.35% to $16.3 million in 2023, then slumped by 40.55% to $9.7 million in 2024.